Twelve-Hour Glycemic Profiles With Meals of High, Medium, or Low Glycemic Load

tion, and worsened glycemic control,whichmightberelatedtothecytochromeP450–mediated metabolic pathway(4,5). The results in this study are an im-portant observation for patients with dia-betes and are consistent with anotherreport that pitavastatin, which is me-tabolized with little involvement of cyto-chrome P450 isoenzymes (4), did notshow these major adverse effects (6). Be-cause pitavastatin has been marketed foronly a few years, further studies with agreater number of subjects and a longerdurationareneededtoestablishthesafetyof this agent.Inconclusion,pitavastatiniseffectivein lowering LDL cholesterol and triglyc-eride levels without affecting glycemiccontrol in patients with diabetes. We be-lieve that this agent must also help pre-vent the development of macrovasculardisease in diabetic patients, as has beenseen with other statins, but this still re-quires confirmation in a controlled clini-cal trial.